PAK1 and Miyoshi myopathy: While the PAK1/2 inhibitor FRAX597 alone was not selectively toxic to RAS-dependent MM (Fig. S6I), we hypothesized that it could synergize with a direct RAS inhibitor by lowering oncogenic RAS levels.